TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00665379

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Compression therapy (Trico bandages)
Description: Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Compression therapy (C2L bandages)
Description: Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
Study: NCT02756052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct-current stimulation
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study: NCT00425620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SinuNase
Description: Lavage
Study: NCT01523808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
Study: NCT06115434

Intervention type: PROCEDURE
Intervention: cystectomy
Description: cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.

Intervention type: PROCEDURE
Intervention: cystectomy
Description: cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
Study: NCT01876732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
Study: NCT02653105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OLFM4
Description: patient have an additional blood test every 6 months for dosing OLFM4
Study: NCT03441763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emed foot device
Description: foot pressure will be measure by using emed foot pressure system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emed foot device
Description: foot pressure will be measure by using emed foot pressure system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emed foot device
Description: foot pressure will be measure by using emed foot pressure system
Study: NCT04879082

Intervention type: OTHER
Intervention: Professional course, occupational exposures
Description: The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past.
Study: NCT02169154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Diclofenac Sodium
Description: 1% diclofenac sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Diclofenac Sodium
Description: 1% diclofenac sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Diclofenac Sodium
Description: 1% diclofenac sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Menthol
Description: 3% Menthol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Menthol
Description: 3% Menthol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.09% Menthol
Description: 0.09% Menthol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.09% Menthol
Description: 0.09% Menthol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.2% Sodium Lauryl Sulfate
Description: 0.2% Sodium Lauryl Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline
Study: NCT00800163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Activation/Immediate Transfer
Description: ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
Study: NCT04292093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation training
Description: The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
Study: NCT03293277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine
Study: NCT04292093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home control activity
Description: The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
Study: NCT02675348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Beef Protein
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: whey Protein
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: CHO
Description: Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
Study: NCT04203329

Intervention type: DEVICE
Intervention: Femoral Venous Vascular Closure
Description: Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.

Intervention type: DEVICE
Intervention: Femoral Venous Vascular Closure
Description: Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
Study: NCT04569318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Beam
Description: One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
Study: NCT02559518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
Study: NCT04203329

Intervention type: DEVICE
Intervention: Femoral Venous Vascular Closure
Description: Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
Study: NCT03974191

Intervention type: OTHER
Intervention: Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.
Description: 13-year prospective longitudinal cohort study
Study: NCT03274596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02899585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score
Study: NCT01018524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall reconstruction
Description: suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall reconstruction
Description: suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall reconstruction
Description: suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal wall reconstruction
Description: suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
Study: NCT00574743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated Mycophenolate Sodium
Study: NCT00762099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pre-operative dose 150 mg Post-operative dose 75 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/sugar tabs will look identical to active drug.
Study: NCT01456936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Triple dummy placebo for each treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate
Description: Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion hydrochloride
Description: Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Patch
Description: Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
Study: NCT01927965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide™ 001
Description: Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
Study: NCT01607177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message reminders
Description: Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
Study: NCT03462836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ketamine/lidocaine/IV PCA apply
Description: In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA only apply
Description: IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
Study: NCT02654587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSE2101
Study: NCT00486330

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine, Tipranavir and ritonavir
Description: After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
Study: NCT01057758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN
Description: Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
Study: NCT03852836

Intervention type: OTHER
Group type: OTHER
Intervention: ultra-rapid acquisition of bile ducts images
Description: On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.

Intervention type: OTHER
Group type: OTHER
Intervention: ultra-rapid acquisition of bile ducts images
Description: On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
Study: NCT04555265

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency ablation or microwave ablation
Description: Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
Study: NCT01241292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-901608 (Elotuzumab) 10 mg
Description: Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-901608 (Elotuzumab) 20 mg
Description: Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
Study: NCT00382135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20mg tadalafil tablet taken by mouth once a day for 40 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 40 weeks
Study: NCT02654587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study: NCT02676791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
Study: NCT03038503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
Study: NCT03662048

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safe
Description: Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safe
Description: Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
Study: NCT00783887

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample of 5 ml